![As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/FiercePharma-1511795226/trelegy.png?VersionId=9ZF.d_etbLV7zCq2is7cCwUDiksDCDFI)
As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma
![As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/FiercePharma-1511795226/trelegy.png?VersionId=9ZF.d_etbLV7zCq2is7cCwUDiksDCDFI)
As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma
![Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA | SpringerLink Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43441-021-00372-y/MediaObjects/43441_2021_372_Fig3_HTML.png)
Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA | SpringerLink
![GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort discounts | Fierce Pharma GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort discounts | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/2016-08/Symbicort_0.jpg?VersionId=QNXDWBWqljL6aUGK_Fnn9V0Ngc30FJ8i)